COMPANY:

Previse

"Previse...today announced the company presented prospective real-world clinical utility data for Esopredict at the 2024 American College of Gastroenterology Annual Scientific Meeting (ACG) being held October 25-30 in Philadelphia, PA and virtually."

"Gastrointestinal health firm Previse said Tuesday that it has been awarded a $1.8 million grant from the National Institutes of Health for the development and commercialization of an esophageal cancer screening test."

"Previse, maker of Esopredict, a clinically available epigenetic test to assess the risk of esophageal cancer developing in patients with Barrett's esophagus was awarded a prestigious and highly competitive $1.8M STTR (Small Business Technology Transfer) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH)....The grant will further support Previse's collaboration with investigators at the Johns Hopkins University School of Medicine and clinical sites in East Africa. The funding will accelerate the development of a non-endoscopic screening test for esophageal squamous cell carcinoma (ESCC), a highly lethal form of esophageal cancer. The funds will also underpin early commercialization efforts in the U.S. and establish a commercialization pathway in East Africa, ensuring global access to accurate, affordable, and practical ESCC detection."

"Previse..announced today that its clinical validation study results for its flagship assay, Esopredict, were published in the American Journal of Gastroenterology (AJG). The publication, "Validation of an Epigenetic Prognostic Assay to Accurately Risk Stratify Patients with Barrett's Esophagus," highlights Esopredict, a first-in-class DNA methylation test for identifying patients with precancerous Barrett's esophagus (BE) who are likely to progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in the future."

"Previse said on Thursday that it has been awarded a $1.8 million grant from the National Institutes of Health to support additional clinical testing of Esopredict, the company's recently launched laboratory-developed real-time PCR test for esophageal cancer risk."

"Previse...announced details on Monday, May 8, of two studies presented during Digestive Disease Week® 2023, held May 6-9 in Chicago. Both analyses clinically validate use of biomarkers to detect and assess risk of esophageal cancer developing in patients with Barrett’s esophagus."

"Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™....In addition to launching Esopredict™, Previse also raised a $3M seed round, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors."